Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Alpha Tau enters sponsored research agreement with MD Anderson to study Alpha DaRT in breast cancer

Jan. 21, 2022

New three-prime repair exonuclease 1 inhibitors described by Tempest Therapeutics

Jan. 21, 2022

New macrophage migration inhibitory factor inhibitors identified at Immunophage Biomedical

Jan. 21, 2022

Targeting PARP could fight cancer-associated virus

Jan. 20, 2022

DNA-PK activates survival kinase AKT in response to DNA damage

Jan. 20, 2022

Jiangsu Hengrui Medicine and Shanghai Hengrui Pharmaceutical patent new ATR kinase inhibitors

Jan. 20, 2022

Eisbach Bio and MD Anderson partner to target synthetic lethality in cancer

Jan. 19, 2022

Sodium salt of a quinoline derivative shows anticancer efficacy in vivo

Jan. 19, 2022

Yes targeting useful for treatment of HCC, researchers suggest

Jan. 19, 2022

Charite-Universitaetsmedizin Berlin, Sapreme Technologies present new saponin derivatives

Jan. 19, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...